All News
Filter News
Found 5,710 articles
-
Lexicon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
8/2/2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2022 and provided an update on key milestones.
-
Dystrophic Epidermolysis Bullosa Treatment Market Size to Hit US$ 715 Million by 2030
8/2/2022
As per Vision research Reports, the global dystrophic epidermolysis bullosa treatment market size is predicted to hit around US$ 715 million by 2030 from valued US$ 415 Mn in 2020, expanding growth at a CAGR of 5.1% from 2022 to 2030.
-
InMed updated its INM-755 for patients with epidermolysis bullosa, Seagen and Astellas announced positive topline results for Padcev with Merck’s Keytruda, and more.
-
CymaBay Completes Enrollment for the RESPONSE Global Phase 3 Study Evaluating Seladelpar for Patients with Primary Biliary Cholangitis
8/1/2022
CymaBay Therapeutics, Inc. today announced the completion of enrollment for RESPONSE, a global Phase 3 study evaluating seladelpar for patients with Primary Biliary Cholangitis (PBC).
-
SciSparc Signs Clinical Trial Agreement with Yale University to Conduct its Phase IIb Trial in Tourette Syndrome
8/1/2022
SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced the addition of another site of excellence, the Yale Child Study Center at Yale University, to its Phase IIb clinical trial for SCI-110 in patients suffering from Tourette Syndrome ("TS").
-
Rhinoconjunctivitis Market is Driven by Increasing Prevalence of Ocular Allergies
8/1/2022
Wilmington, Delaware, United States, Transparency Market Research Inc.: Rhinoconjunctivitis is an allergy that is the combination of conjunctivitis and rhinitis and affects the conjunctiva mucosa and nasal mucosa.
-
Dr. Reddy's Laboratories enters into a licensing agreement with Slayback Pharma to obtain exclusive rights in the first-to-file ANDA for the private label version of Lumify® in the U.S.
7/29/2022
Dr. Reddy’s Laboratories Ltd. today announced that it has entered into a licensing agreement with Princeton, New Jersey based Slayback Pharma LLC (“Slayback”), to acquire rights in Slayback’s Brimonidine Tartrate Ophthalmic Solution 0.025%, the private label equivalent of Lumify® in U.S. Lumify® is an over-the-counter (OTC) eyedrop that can be used to relieve redness of the eye due to minor eye irritations.
-
Sen-Jam Pharmaceutical, The World's Most Resourceful Drug Innovator, Turns To Crowdfunding To Secure Financing To Advance Critical Therapeutics
7/29/2022
Sen-Jam Pharmaceutical, an innovative life sciences company developing a portfolio of revolutionary anti-inflammatories by repurposing existing molecules for novel combination therapy, started and will be completing this weekend, a Community Fundraising effort to drive drug development.
-
Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease
7/28/2022
Acer Therapeutics Inc. and RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate the efficacy and safety of ACER-001.
-
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDsPrescription Drug User Fee Act (PDUFA) target action date set for January 15, 2023
7/28/2022
Acer Therapeutics Inc. (Nasdaq: ACER) (Acer) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), today announced the U.S. Food and Drug Administration (FDA) has accepted for review Acer’s resubmitted New Drug Application (NDA) for ACER-001 (sodium phenylbutyrate) for oral suspension for the treatment of patients with urea cycle disorders (UCDs).
-
Bronchopulmonary Dysplasia Market Report on Rising Demand, Future Scope and Regional Forecast by 2030
7/28/2022
The latest market analysis report published by Reports and Data, titled ‘Global Bronchopulmonary Dysplasia Market – Forecast to 2030,’ thoroughly examines the Bronchopulmonary Dysplasia industry to provide essential data & information for the targeted readers.
-
Opioid Use Disorder Market Outlook, Competitive Landscape and Forecasts to 2027
7/27/2022
Wilmington, Delaware, United States, Transparency Market Research Inc.: Opioids are used for pain relief.
-
Researchers at the Institut Pasteur in Paris, France have found that the COVID-19 virus enters the brain through nanotubes to cause debilitating neurologic symptoms.
-
Rapid Therapeutic Science Laboratories File S1 and completes Mid-Year Strategy Review
7/26/2022
Rapid Therapeutics Science Laboratories (OTC: RTSL) ("Rapid Therapeutic'' or the "Company"), a growth-oriented aerosol manufacturing company focused on natural relief innovations through trusted aerosol delivery, announces today that it has filed it’s S1 and has completed mid-year strategy review in conjunction with the filing.
-
Teva Reports Second Quarter 2022 Financial Results
7/26/2022
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended June 30, 2022.
-
European Commission Approves RINVOQ® (upadacitinib) for the Treatment of Adults With Moderate to Severe Ulcerative Colitis
7/26/2022
AbbVie (NYSE: ABBV) today announced the European Commission (EC) approved RINVOQ® (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
-
InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa
7/25/2022
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today provided an update on its Phase 2 clinical trial using investigational drug INM-755 cannabinol (“CBN”) cream for the treatment of patients with epidermolysis bullosa (“EB”).
-
Todos Medical Announces Preprint of Chronic Long COVID Case Study #8 of Paxlovid® Treatment Followed by Tollovid™ Dietary Supplementation
7/22/2022
Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned joint venture 3CL Pharma Ltd. reported the preprint in ResearchGate of case study #8 entitled “A Case Review.
-
Dr. Reddy’s Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market
7/22/2022
Dr. Reddy’s Laboratories Ltd. announced the first-to-market launch of over-the-counter Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg Extended Release Tablets, USP, the store-brand equivalent of Allegra-D® 24 HR in the U.S. market, as approved by the U.S. Food and Drug Administration.
-
Freeline Therapeutics' hemophilia B drug demonstrated the strong possibility that a single injection of FLT180a, an experimental gene therapy, can reduce or eliminate the need for weekly injections.